Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
12 May 2024
|
19:35 | (Upload log) [Kosar Doraghi (8×)] | |||
|
19:35 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg | ||||
|
19:33 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg | ||||
|
19:32 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg | ||||
|
19:30 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg | ||||
|
19:28 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg | ||||
|
19:24 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg | ||||
|
05:15 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg | ||||
|
05:13 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg |
N 05:30 | Somatrogon-ghla diffhist +12,476 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...") |
11 May 2024
|
22:32 | Mirikizumab-mrkz 3 changes history +5,248 [Rithish Nimmagadda (3×)] | |||
|
22:32 (cur | prev) +13 Rithish Nimmagadda talk contribs | ||||
|
22:31 (cur | prev) 0 Rithish Nimmagadda talk contribs | ||||
|
22:26 (cur | prev) +5,235 Rithish Nimmagadda talk contribs |
N 20:21 | Elfabrio diffhist +3,351 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...") |
N 19:36 | Exxua diffhist +44 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}") |
|
19:09 | Facioscapulo-humeral dystrophy 8 changes history +2,898 [Dj (8×)] | |||
|
19:09 (cur | prev) +29 Dj talk contribs (→History) | ||||
|
18:59 (cur | prev) +191 Dj talk contribs | ||||
|
18:45 (cur | prev) +637 Dj talk contribs (→Pathophysiology) | ||||
|
18:41 (cur | prev) +138 Dj talk contribs | ||||
|
17:59 (cur | prev) +789 Dj talk contribs (→Classification) | ||||
|
17:52 (cur | prev) −5 Dj talk contribs | ||||
|
17:51 (cur | prev) +363 Dj talk contribs | ||||
|
17:43 (cur | prev) +756 Dj talk contribs |
12:13 | User:Archana.vajjala diffhist +62 Archana.vajjala talk contribs (→Interests) |
10 May 2024
21:12 | Stress ulcer diffhist +1,682 Badgettrg talk contribs (→Drug classes and options available) |
|
19:11 | Sotagliflozin 5 changes history +3,623 [Alen Antony (5×)] | |||
|
19:11 (cur | prev) +829 Alen Antony talk contribs | ||||
|
18:12 (cur | prev) +833 Alen Antony talk contribs | ||||
|
17:54 (cur | prev) +545 Alen Antony talk contribs | ||||
|
17:46 (cur | prev) +744 Alen Antony talk contribs | ||||
|
17:12 (cur | prev) +672 Alen Antony talk contribs |
|
m 17:02 | Non-degenerate nucleotides per response element 4 changes history +94 [Marshallsumter (4×)] | |||
m |
|
17:02 (cur | prev) +53 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
06:35 (cur | prev) −8 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
06:32 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
06:16 (cur | prev) +49 Marshallsumter talk contribs (→Tabulation of counts) |
04:13 | Electronic medical record diffhist +119 Badgettrg talk contribs (→Problem lists) |
01:58 | User:Archana.vajjala diffhist +2 Archana.vajjala talk contribs |
9 May 2024
|
N 23:59 | Sotagliflozin 3 changes history +1,667 [Alen Antony (3×)] | |||
|
23:59 (cur | prev) +19 Alen Antony talk contribs | ||||
|
15:17 (cur | prev) +1,230 Alen Antony talk contribs | ||||
N |
|
04:57 (cur | prev) +418 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}") |
14:35 | User:Rithish Nimmagadda diffhist +123 Rithish Nimmagadda talk contribs (→Education) |
|
N 14:32 | Epcoritamab-bysp 3 changes history +11,459 [Rithish Nimmagadda (3×)] | |||
|
14:32 (cur | prev) +11,409 Rithish Nimmagadda talk contribs | ||||
|
13:14 (cur | prev) +4 Rithish Nimmagadda talk contribs | ||||
N |
|
13:10 (cur | prev) +46 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}") |
|
N 10:45 | FUTIBATINIB 2 changes history +1,225 [Hafiza Amna Qadeer (2×)] | |||
|
10:45 (cur | prev) −12 Hafiza Amna Qadeer talk contribs | ||||
N |
|
10:37 (cur | prev) +1,237 Hafiza Amna Qadeer talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...") |
8 May 2024
21:38 | Template:KDRG diffhist +174 Kosar Doraghi talk contribs |
21:38 | EXXUA diffhist +11 Kosar Doraghi talk contribs |